Biome Australia Limited (BIO.AX)
AUD 0.46
(-2.15%)
AUD 0.46
(-2.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 5.37 Million AUD | 35.24% |
| 2023 | 3.97 Million AUD | 130.16% |
| 2022 | 1.72 Million AUD | 87.63% |
| 2021 | 920 Thousand AUD | -7.73% |
| 2020 | 997.1 Thousand AUD | 63.24% |
| 2019 | 610.83 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.02 Million AUD | 215.15% |
| 2024 Q4 | 5.37 Million AUD | 0.0% |
| 2024 FY | 5.37 Million AUD | 35.24% |
| 2024 Q2 | 5.02 Million AUD | 0.0% |
| 2023 Q2 | 3.02 Million AUD | 0.0% |
| 2023 FY | 3.97 Million AUD | 130.16% |
| 2023 Q3 | 3.97 Million AUD | 31.4% |
| 2023 Q1 | 3.02 Million AUD | 75.17% |
| 2023 Q4 | 1.59 Million AUD | -59.84% |
| 2022 Q2 | 1.44 Million AUD | 0.0% |
| 2022 FY | 1.72 Million AUD | 87.63% |
| 2022 Q4 | 1.72 Million AUD | 0.0% |
| 2022 Q3 | 1.72 Million AUD | 19.22% |
| 2022 Q1 | 1.44 Million AUD | 57.41% |
| 2021 Q4 | 919.79 Thousand AUD | -0.0% |
| 2021 Q3 | 919.79 Thousand AUD | 0.0% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 FY | 920 Thousand AUD | -7.73% |
| 2020 FY | 997.1 Thousand AUD | 63.24% |
| 2019 FY | 610.83 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -51.678% |
| Acrux Limited | 5.68 Million AUD | 5.517% |
| Actinogen Medical Limited | 1.61 Million AUD | -232.634% |
| AnteoTech Limited | 4.07 Million AUD | -31.851% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -121.421% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -161.265% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -1651.11% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 0.966% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -56.801% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -470.689% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -1358.358% |
| Biotron Limited | 737.5 Thousand AUD | -628.57% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -43.975% |
| BTC Health Limited | 203.94 Thousand AUD | -2534.624% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 58.032% |
| CSL Limited | 27.88 Billion AUD | 99.981% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 35.509% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 80.886% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -358.84% |
| Dimerix Limited | 13.89 Million AUD | 61.324% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -27.053% |
| Hexima Limited | 248.67 Thousand AUD | -2060.801% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -413.881% |
| Immuron Limited | 2.84 Million AUD | -89.164% |
| Immutep Limited | 10.97 Million AUD | 51.061% |
| Imugene Limited | 33.14 Million AUD | 83.788% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -1144.877% |
| Memphasys Limited | 5.59 Million AUD | 3.918% |
| Nanollose Limited | 465.64 Thousand AUD | -1053.945% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 87.435% |
| Noxopharm Limited | 1.28 Million AUD | -316.98% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -6171.096% |
| Nyrada Inc. | 855.63 Thousand AUD | -527.987% |
| Orthocell Limited | 22.08 Million AUD | 75.667% |
| PharmAust Limited | 896.6 Thousand AUD | -499.289% |
| Patrys Limited | 691.36 Thousand AUD | -677.196% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -49.909% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -230.474% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -131.052% |
| PYC Therapeutics Limited | 10.18 Million AUD | 47.239% |
| Race Oncology Limited | 1.91 Million AUD | -180.38% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 87.975% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 66.192% |
| Starpharma Holdings Limited | 8.69 Million AUD | 38.224% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 97.845% |
| Tissue Repair Ltd | 1.35 Million AUD | -297.753% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 42.572% |